Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Patient and caregiver priorities of treatment characteristics influencing preferences for tyrosine kinase inhibitors in anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: February 06, 2026
Evaluating Diagnostic and Treatment Timelines for ALK-Positive NSCLC Patients: Results From a Global Registry.
Journal: Clinical lung cancer
Published: January 30, 2025
Economic Impact of Next-Generation Sequencing Versus Single-Gene Testing to Detect Genomic Alterations in Metastatic Non-Small-Cell Lung Cancer Using a Decision Analytic Model.
Journal: JCO precision oncology
Published: December 01, 2019
Reimbursement landscape for molecular testing in non-small cell lung cancer (NSCLC).
Journal: The American journal of managed care
Published: April 25, 2018
Economic analysis of BRAF gene mutation testing in real world practice using claims data: costs of single gene versus panel tests in patients with lung cancer.
Journal: Journal of medical economics
Published: March 09, 2018
Treatment patterns, clinical and economic outcomes of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer receiving ceritinib: a retrospective observational claims analysis.
Journal: Journal of drug assessment
Published: November 27, 2017
Monitoring for and Characterizing Crizotinib Progression: A Chart Review of ALK-Positive Non-Small Cell Lung Cancer Patients.
Journal: Advances in therapy
Published: March 21, 2017
Treatment Patterns and Early Outcomes of ALK-Positive Non-Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review Study.
Journal: Advances in therapy
Published: February 20, 2017
The economic burden of brain metastasis among lung cancer patients in the United States.
Journal: Journal of medical economics
Published: January 07, 2016
Treatment, overall survival, and costs in patients with ALK-positive non-small-cell lung cancer after crizotinib monotherapy.
Journal: Current medical research and opinion
Published: June 02, 2015
Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden.
Journal: Journal of medical economics
Published: January 08, 2015
Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US.
Journal: Journal of medical economics
Published: November 26, 2014
Last Updated: 09/26/2026